# Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

> **NCT06175390** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Curie** · enrollment: 81 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **RADIATION:** 68Ga-FAPI-46 PET/CT
- **BIOLOGICAL:** Tumor samples analysis
- **BIOLOGICAL:** Blood samples analysis: Circulating Tumor DNA

## Key facts

- **NCT ID:** NCT06175390
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2026-08-15
- **Final completion:** 2029-02-15
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175390, "Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06175390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*